2 not yet recruiting, 2 unknown, 1 recruiting. 2 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 2 |
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Heart Failure, Preserved Ejection Fraction: new trials by email Literature Review of Heart Failure, Preserved Ejection Fraction trials Research Report on Heart Failure, Preserved Ejection Fraction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Bimagrumab in Participants With HFpEF Bimagrumab, Placebo - Heart Failure, Diastolic, Diastolic Heart Failure | Phase 2 | Not yet recruiting | Eli Lilly and Company | 540 | 2026-11-01 | 2026-11-06 |
| Randomized Double-blind Controlled Clinical Study of SGLT-2i Combined With Probiotic Preparations in Elderly Patients With HFpEF Henggliflozin Combined with Probiotics, Henggliflozin, double placebo - Heart Failure, Preserved Ejection Fraction | Phase 1 / Phase 2 | Not yet recruiting | The First Affiliated Hospital of Air Force Medicial University | 162 | 2026-07-01 | 2026-07-07 |
| The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction SGLT2 inhibitor - Heart Failure, Preserved Ejection Fraction | Phase 4 | Unknown | Samsung Medical Center | 154 | 2024-05-01 | 2024-04-08 |
| Relative Importance of Cardiovascular Risk Factors and Echocardiographic Parameters Affecting Left Atrial Strain Left atrial reservoir strain - Heart Failure, Diastolic, Heart Failure, Preserved Ejection Fraction | Unknown | Yonsei University | 2500 | 2021-08-01 | 2022-12-06 | |
| Characterization of Heart Failure With Preserved Ejection Fraction cMR, biomarker - Heart Failure, Preserved Ejection Fraction, Cardiac Fibrosis | Not applicable | Recruiting | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 500 | 2014-12-04 | 2024-02-05 |
Heart Failure, Diastolic (5) · Sarcopenia (1)
Cardiovascular Diseases (5) · Heart Diseases (5) · Heart Failure (5) · Atrophy (1) · Muscular Atrophy (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Neuromuscular Manifestations (1) · Pathological Conditions, Anatomical (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Biomarkers (1) · Probiotics (1) · Sodium-Glucose Transporter 2 Inhibitors (1) · bimagrumab (1)
Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Eli Lilly and Company (1) · Samsung Medical Center (1) · The First Affiliated Hospital of Air Force Medicial University (1) · Yonsei University (1)
South Korea (2) · Belgium (1) · China (1) · Hungary (1) · Italy (1) · Poland (1) · United States (1)
Anne Catherine Pouleur (1) · Jeong Hoon Yang, MD, PhD (1)
PMID 30086783, PMID 37900564, PMID 39077419, PMID 40121452, PMID 41495328